Literature DB >> 226484

Biological and biochemical observations on isolates of EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas.

D H Crawford, M A Epstein, G W Bornkamm, B G Achong, S Finerty, J L Thompson.   

Abstract

Foetal, adult seronegative, and cotton-top marmoset lymphocytes have been transformed into cell lines by EB virus from the malignant epithelial cells of two nasopharyngeal carcinomas. The nature of the cell lines was checked by karyotyping and by light and electron microscopy, and the presence of the EB virus genome was demonstrated by immunofluorescence tests. Immunofluorescence also showed the incidence of EB virus-producing cells in each line and this was checked by electron microscopy and the use of a lymphocyte transformation assay. Two foetal-derived lines did not produce virus spontaneously, could not be activated with various inducers, and were found by DNA reassociation kinetics to carry only small numbers of genome copies per cell. An adult-derived line produced virus, could be activated to produce more, and provided enough infectivity to transform marmoset cells. The resulting marmoset line made profuse transforming virus; it thus provides the first abundant source of NPC-derived infectious EB virus for comparative studies. The results are discussed in relation to the interactions with comparable target cells of EB virus from normal individuals and from patients with other diseases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226484     DOI: 10.1002/ijc.2910240305

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Biochemical characterization of Epstein-Barr virus nuclear antigen 2A.

Authors:  F A Grässer; P Haiss; S Göttel; N Mueller-Lantzsch
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  Genomic sequence analysis of Epstein-Barr virus strain GD1 from a nasopharyngeal carcinoma patient.

Authors:  Mu-Sheng Zeng; Da-Jiang Li; Qing-Lun Liu; Li-Bing Song; Man-Zhi Li; Ru-Hua Zhang; Xing-Juan Yu; Hui-Min Wang; Ingemar Ernberg; Yi-Xin Zeng
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B.

Authors:  J R Arrand; L S Young; J D Tugwood
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells.

Authors:  K P Mann; D Staunton; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

5.  EB virus induction is associated with B-cell maturation.

Authors:  D H Crawford; I Ando
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

6.  Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection.

Authors:  B Neuhierl; R Feederle; W Hammerschmidt; H J Delecluse
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-30       Impact factor: 11.205

7.  Identification and characterization of an Epstein-Barr virus early antigen that is encoded by the NotI repeats.

Authors:  C M Nuebling; N Mueller-Lantzsch
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

8.  Expression of a nuclear and a cytoplasmic Epstein-Barr virus early antigen after DNA transfer: cooperation of two distant parts of the genome for expression of the cytoplasmic antigen.

Authors:  K Takaki; A Polack; G W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Deletion of the nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal repeat to the DSL region.

Authors:  G W Bornkamm; J Hudewentz; U K Freese; U Zimber
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

10.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.